Advertisement

NeuroMolecular Medicine

, Volume 7, Issue 1–2, pp 37–50 | Cite as

Cannabinoid receptors and their role in neuroprotection

  • Mario van der Stelt
  • Vincenzo Di MarzoEmail author
Original Article

Abstract

Two G protein-coupled receptors for marijuana’s psychoactive component, Δ9-tetrahydrocannabinol, have been cloned to date, the cannabinoid CB1 and CB2 receptors. These two proteins, the endogenous lipids that activate them, also known as endocannabinoids, and the proteins for the biosynthesis and inactivation of these ligands constitute the endocannabinoid system. Evidence has accumulated over the last few years suggesting that endocannabinoid-based drugs may potentially be useful to reduce the effects of neurodegeneration. In fact, exogenous and endogenous cannabinoids were shown to exert neuroprotection in a variety of in vitro and in vivo models of neuronal injury via different mechanisms, such as prevention of excitotoxicity by cannabinoid CB1-mediated inhibition of glutamatergic transmission, reduction of calcium influx, anti-oxidant activity, activation of the phosphatidylinositol 3-kinase/protein kinase B pathway, induction of phosphorylation of extracellular regulated kinases and the expression of transcription factors and neurotrophins, lowering of cerebrovasoconstriction and induction of hypothermia. The release of endocannabinoids during neuronal injury may constitute a protective response. If this neuroprotective function of cannabinoid receptor activation can be transferred to the clinic, it might represent an interesting target to develop neuroprotective agents.

Index Entries

Endocannabinoid anandamide 2-arachidonoylglycerol cannabinoid-receptor signaling neuromodulatory role of endocannabinoids glutamate excitotoxicity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abood M. E., Rizvi G., Sallapudi N., and McAllister S. D. (2001) Activation of the CB(1) cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 309, 197–201.PubMedCrossRefGoogle Scholar
  2. Andersson M., Jacobsson S. O., Jonsson K. O., Tiger G., and Fowler C. J. (2000) Neurotoxicity of glutamate in chick telencephalon neurons: reduction of toxicity by preincubation with carbachol, but not by the endogenous fatty acid amides anandamide and palmitoylethanolamide. Arch. Toxicol. 74, 161–164.PubMedCrossRefGoogle Scholar
  3. Bayewitch M., Rhee M. H., Avidor-Reiss T., Breuer A., Mechoulam R., and Vogel Z. (1996) (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J. Biol. Chem. 271, 9902–9905.PubMedCrossRefGoogle Scholar
  4. Benito C., Nunez E., Tolon R. M., et al. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J. Neurosci. 23, 11,136–11,141.Google Scholar
  5. Berdyshev E. V., Schmid P. C., Krebsbach R. J., et al. (2001) Cannabinoid-receptor-independent cell signalling by N-acylethanolamines. Biochem. J. 360, 67–75.PubMedCrossRefGoogle Scholar
  6. Berger C., Schmid P., Schabitz W., Wolf M., Schwab S., and Schmid H. (2004) Massive accumlation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J. Neurochem. 88, 1159–1167.PubMedCrossRefGoogle Scholar
  7. Bisogno T., Hanus L., De Petrocellis L., et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845–852.PubMedCrossRefGoogle Scholar
  8. Bisogno T., Howell F., Williams G., et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell. Biol. 163, 463–468.PubMedCrossRefGoogle Scholar
  9. Bouaboula M., Bourrie B., Rinaldi-Carmona M., Shire D., Le Fur G., and Casellas P. (1995b) Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270, 13,973–13,980.Google Scholar
  10. Bouaboula M., Poinot-Chazel C., Bourrie B., et al. (1995a) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312, 637–641.PubMedGoogle Scholar
  11. Bouaboula M., Poinot-Chazel C., Marchand J., et al. (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237, 704–711.PubMedCrossRefGoogle Scholar
  12. Braida D., Pozzi M., and Sala M. (2000) CP 55,940 protects against ischemia-induced electroencephalographic flattening and hyperlocomotion in Mongolian gerbils. Neurosci. Lett. 296, 69–72.PubMedCrossRefGoogle Scholar
  13. Braida D., Pegorini S., Arcidiacono M., Consalez G., Croci L., and Sala M. (2003) Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci. Lett. 346, 61–64.PubMedCrossRefGoogle Scholar
  14. Breivogel C. S., Griffin G., Di Marzo V., and Martin B. R. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60, 155–163.PubMedGoogle Scholar
  15. Caulfield M. P. and Brown D. A. (1992) Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106, 231–232.PubMedGoogle Scholar
  16. Cernak I., Vink R., Natale J., et al. (2004) The dark side of endocannabinoids: a neurotoxic role for anandamide. J. Cereb. Blood Flow Metab. 24, 564–578.PubMedCrossRefGoogle Scholar
  17. Chan G. C., Hinds T. R., Impey S., and Storm D. R. (1998) Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J. Neurosci. 18, 5322–5332.PubMedGoogle Scholar
  18. Chemin J., Monteil A., Perez-Reyes E., Nargeot J., and Lory P. (2001) Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. Embo. J. 20, 7033–7040.PubMedCrossRefGoogle Scholar
  19. Childers S. R., Sexton T., and Roy M. B. (1994) Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47, 711–715.PubMedCrossRefGoogle Scholar
  20. Clement A., Hawkins E., Lichtman A., and Cravatt B. (2003) Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 23, 3916–3923.PubMedGoogle Scholar
  21. Deadwyler S. A., Hampson R. E., Mu J., Whyte A., and Childers S. (1995) Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 273, 734–743.PubMedGoogle Scholar
  22. Deadwyler S. A., Hampson R. E., Bennett B. A., et al. (1993) Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptors Channels 1, 121–134.PubMedGoogle Scholar
  23. Di Marzo V. (1998) “Endocannabinoids” and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta. 1392, 153–175.PubMedGoogle Scholar
  24. Di Marzo V., Bisogno T., and De Petrocellis L. (2000a) Endocannabinoids: new targets for drug development. Curr. Pharm. Des. 6, 1361–1380.PubMedCrossRefGoogle Scholar
  25. Di Marzo V., Melck D., Bisogno T., and De Petrocellis L. (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521–528.PubMedCrossRefGoogle Scholar
  26. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J. C., and Piomelli D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686–691.PubMedCrossRefGoogle Scholar
  27. Di Marzo V., Breivogel C. S., Tao Q., et al. (2000b) Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75, 2434–2444.PubMedCrossRefGoogle Scholar
  28. Dirnagl U., Iadecola C., and Moskowitz M. A. (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22, 391–397.PubMedCrossRefGoogle Scholar
  29. El-Remessy A., Khalil I., Matragoon S., et al. (2003) Neuroprotective effect of (−)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-d-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am. J. Pathol. 16, 1997–2008.Google Scholar
  30. Felder C. C., Briley E. M., Axelrod J., Simpson J. T., Mackie K., and Devane W. A. (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA 90, 7656–7660.PubMedCrossRefGoogle Scholar
  31. Felder C. C., Joyce K. E., Briley E. M., et al. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors Mol. Pharmacol. 48, 443–450.PubMedGoogle Scholar
  32. Franklin A., Parmentier-Batteur S., Walter M., Greenberg D., and Stella N. (2003) Palmitoylethanolamide increases after focal cerbral ischemia and potentiates microglial cell motility. J. Neurosci. 23, 7767–7775.PubMedGoogle Scholar
  33. Gallily R., Breuer A., and Mechoulam R. (2000) 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur. J. Pharmacol. 406, R5–7.PubMedCrossRefGoogle Scholar
  34. Galve-Roperh I., Rueda D., Gomez D. P., Velasco G., and Guzman M. (2002) Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol. Pharmacol. 62, 1385–1392.PubMedCrossRefGoogle Scholar
  35. Galve-Roperh I., Sanchez C., Cortes M. L., del Pulgar T. G., Izquierdo M., and Guzman M. (2000) Antitumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6, 313–319.PubMedCrossRefGoogle Scholar
  36. Gebremedhin D., Lange A. R., Campbell W. B., Hillard C. J., and Harder D. R. (1999) Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current Am. J. Physiol. 276, H2085-H2093.PubMedGoogle Scholar
  37. Gerdeman G. L., Ronesi J., and Lovinger D. M. (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 25, 25.Google Scholar
  38. Glass M. and Felder C. C. (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17, 5327–5333.PubMedGoogle Scholar
  39. Gomez Del Pulgar T., De Ceballos M. L., Guzman M., and Velasco G. (2002) Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway. J. Biol. Chem. 277, 36,527–36,533.CrossRefGoogle Scholar
  40. Gomez del Pulgar, Velasco G., and Guzman M. (2000) The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J. 347, 369–373.CrossRefGoogle Scholar
  41. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., and Hipkin R. W. (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 57(5), 1045–1050.PubMedGoogle Scholar
  42. Grant E. R., Dubin A. E., Zhang S. P., Zivin R. A., and Zhong Z. (2002) Simultaneous intracellular calcium and sodium flux imaging in human vanilloid receptor 1 (VR1)-transfected human embryonic kidney cells: a method to resolve ionic dependence of VR1-mediated cell death. J. Pharmacol. Exp. Ther. 300, 9–17.PubMedCrossRefGoogle Scholar
  43. Guzman M., Galve-Roperh I., and Sanchez C. (2001) Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol. Sci. 22, 19–22.PubMedCrossRefGoogle Scholar
  44. Hajos N. and Freund T. (2002) Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43, 503.PubMedCrossRefGoogle Scholar
  45. Hajos N., Ledent C., and Freund T. F. (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106, 1–4.PubMedCrossRefGoogle Scholar
  46. Hampson A. J., Grimaldi M., Axelrod J., and Wink D. (1998a) Cannabidiol and (−)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 95, 8268–8273.PubMedCrossRefGoogle Scholar
  47. Hampson A. J., Bornheim L. M., Scanziani M., et al. (1998b) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 70, 671–676.PubMedCrossRefGoogle Scholar
  48. Hampson R. E., Foster T C., and Deadwyler S. A. (1989) Effects of delta-9-tetrahydrocannabinol on sensory evoked hippocampal activity in the rat: principal components analysis and sequential dependency. J. Pharmacol. Exp. Ther. 251, 870–877.PubMedGoogle Scholar
  49. Hansen H. H., Ikonomidou C., Bittigau P., Hansen S. H., and Hansen H. S. (2001a) Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J. Neurochem. 76, 39–46.PubMedCrossRefGoogle Scholar
  50. Hansen H. H., Azcoitia I., Pons S., et al. (2002) Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J. Neurochem. 82, 154–158.PubMedCrossRefGoogle Scholar
  51. Hansen H. H., Schmid P. C., Bittigau P., et al. (2001b) Anandamide, butnot2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78, 1415–1427.PubMedCrossRefGoogle Scholar
  52. Hansen H. S., Lauritzen L., Strand A. M., Vinggaard A. M., Frandsen A., and Schousboe A. (1997) Characterization of glutamate-induced formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons. J. Neurochem. 69, 753–761.PubMedCrossRefGoogle Scholar
  53. Hanus L., Abu-Lafi S., Fride E., et al. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 98, 3662–3665.PubMedCrossRefGoogle Scholar
  54. Henry D. J. and Chavkin C. (1995) Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Lett. 186, 91–94.PubMedCrossRefGoogle Scholar
  55. Herkenham M., Lynn A. B., Johnson M. R., Melvin L. S., de Costa B. R., and Rice K. C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563–583.PubMedGoogle Scholar
  56. Herkenham M., Lynn A. B., Little M. D., et al. (1990) Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA 87, 1932–1936.PubMedCrossRefGoogle Scholar
  57. Howlett A. C., and Mukhopadhyay S. (2000) Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem. Phys. Lipids 108, 53–70.PubMedCrossRefGoogle Scholar
  58. Howlett A. C. Barth F., Bonner T. I., et al. (2002) International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev. 54, 161–202.Google Scholar
  59. Howlett A. C. (1995) Pharmacology of cannabinoid receptors Annu. Rev. Pharmacol. Toxicol. 35, 607–634.PubMedCrossRefGoogle Scholar
  60. Huang S. M., Bisogno T., Trevisani M., et al. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA 99, 8400–8405.PubMedCrossRefGoogle Scholar
  61. Jacobsson S. O., Wallin T., and Fowler C. J. (2001) Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 299, 951–959.PubMedGoogle Scholar
  62. Jin K. L., Mao X. O., Goldsmith P. C., and Greenberg D. A. (2000) CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 48, 257–261.PubMedCrossRefGoogle Scholar
  63. Kermer P., Klocker N., and Bahr M. (1999) Neuronal death after brain injury. Models, mechanisms, and therapeutic strategies in vivo. Cell Tissue Res. 298, 383–395.PubMedCrossRefGoogle Scholar
  64. Khaspekov L., Brenz Verca M., Frumkina L. E., Hermann H., Marsicano G., and Lutz B. (2004) Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur. J. Neurosci. 19, 1691–1698.PubMedCrossRefGoogle Scholar
  65. Kreitzer A. C. and Regehr W. G. (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 29, 717–727.PubMedCrossRefGoogle Scholar
  66. Leker R., Gai N., Mechoulam R., and Ovadia H. (2003) Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 34, 2000–2006.PubMedCrossRefGoogle Scholar
  67. Lipton S. (2003) Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv. Ophthalmol. Suppl. 1, S38–46.CrossRefGoogle Scholar
  68. Liu J., Gao B., Mirshahi F., et al. (2000) Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. 346, 835–840.PubMedCrossRefGoogle Scholar
  69. Louw D. F., Yang F. W., and Sutherland G. R. (2000) The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. 857, 183–187.PubMedCrossRefGoogle Scholar
  70. Lutz B. (2004) On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem. Pharmacol. 68:1691–1698.PubMedCrossRefGoogle Scholar
  71. Maccarrone M., Lorenzon T., Bari M., Melino G., and Finazzi-Agro A. (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275, 31,938–31,945.Google Scholar
  72. Mackie K., Devane W. A., and Hille B. (1993) Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44, 498–503.PubMedGoogle Scholar
  73. Mackie K. and Hille B. (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA 89, 3825–3829.PubMedCrossRefGoogle Scholar
  74. Mackie K., Lai Y., Westenbroek R., and Mitchell R. (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15(10), 6552–6561.PubMedGoogle Scholar
  75. Maingret F., Patel A. J., Lazdunski M., and Honore E. (2001) The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. Embo. J. 20, 47–54.PubMedCrossRefGoogle Scholar
  76. Marsicano G., Moosmann B., Hermann H., Lutz B., and Behl C. (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80, 448–456.PubMedCrossRefGoogle Scholar
  77. Marsicano G., Goodenough S., Monory K., et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84–88.PubMedCrossRefGoogle Scholar
  78. Martinez-Orgado J., Fernandez-Frutos B., Gonzalez R., et al. (2003) Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Brain Res. Mol. 114, 132–139.CrossRefGoogle Scholar
  79. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., and Bonner T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564.PubMedCrossRefGoogle Scholar
  80. Mauler F., Mittendorf J., Horvath E., and De Vry J. (2002) Characterization of the diarylether sulfonylester (−)-(R)-3-(2- hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J. Pharmacol. Exp. Ther. 302, 359–368.PubMedCrossRefGoogle Scholar
  81. McAllister S. D., Griffin G., Satin L. S., and Abood M. E. (1999) Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system J. Pharmacol. Exp. Ther. 291, 618–626.PubMedGoogle Scholar
  82. Mechoulam R., Panikashvili D., and Shohami E. (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8, 58–61.PubMedCrossRefGoogle Scholar
  83. Molina-Holgado E., Vela J., Arevalo-Martin A., et al. (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 22, 9742–9753.PubMedGoogle Scholar
  84. Molina-Holgado F., Pinteaux E., Moore J., et al. (2003) Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23, 6470–6474.PubMedGoogle Scholar
  85. Molina-Holgado F., Pinteaux E., Heenan L., Moore J. D., Rothwell N. J., and Gibson R. M. Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling Mol. Cell Neurosci., in press.Google Scholar
  86. Munro S., Thomas K. L., and Abu-Shaar M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61–65.PubMedCrossRefGoogle Scholar
  87. Muthian S., Rademacher D. J., Roelke C. T., Gross G. J., and Hillard C. (2004) Anandamide content is increased and Cb1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neurosci. 129, 743–750.CrossRefGoogle Scholar
  88. Nagayama T., Sinor A. D., Simon R. P., et al. (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19, 2987–2995.PubMedGoogle Scholar
  89. Netzeband J. G., Conroy S. M., Parsons K. L., and Gruol D. L. (1999) Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture. J. Neurosci. 19, 8765–8777.PubMedGoogle Scholar
  90. Nicotera P., Leist M., and Manzo L. (1999) Neuronal cell death: a demise with different shapes. Trends Pharmacol. Sci. 20, 46–51.PubMedCrossRefGoogle Scholar
  91. Ohno-Shosaku T., Maejima T., and Kano M. (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 29, 729–738.PubMedCrossRefGoogle Scholar
  92. Okamoto Y., Morishita J., Tsuboi K., Tonai T., and Ueda N. (2004), Molecular characterization of a phospholipase D generating anandamide and Its congeners. J. Biol. Chem. 279, 5298–5305PubMedCrossRefGoogle Scholar
  93. Pan X., Ikeda S. R., and Lewis D. L. (1996) Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system Mol. Pharmacol. 49, 707–714.PubMedGoogle Scholar
  94. Panikashvili D., Simeonidou C., Ben-Shabat S., et al. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527–531.PubMedCrossRefGoogle Scholar
  95. Parmentier-Batteur S., Jin K., Mao X., Xie L., and Greenberg D. (2002) Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J. Neurosci. 22, 9771–9775.PubMedGoogle Scholar
  96. Pinto J. C., Potie F., Rice K. C., et al. (1994) Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid Mol. Pharmacol. 46, 516–522.PubMedGoogle Scholar
  97. Porter A. C., Sauer J. M., Knierman M. D., et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301, 1020–1024.PubMedCrossRefGoogle Scholar
  98. Priller J., Briley E. M., Mansouri J., Devane W. A., Mackie K., and Felder C. C. (1995) Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors Mol. Pharmacol. 48, 288–292.PubMedGoogle Scholar
  99. Rhee M. H., Bayewitch M., Avidor-Reiss T., Levy R., and Vogel Z. (1998) Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes J. Neurochem. 71, 1525–1534.PubMedCrossRefGoogle Scholar
  100. Robbe D., Kopf M., Remaury A., Bockaert J., and Manzoni O. J. (2002) Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc. Natl. Acad. Sci. USA 99, 8384–8388.PubMedCrossRefGoogle Scholar
  101. Rueda D., Galve-Roperh I., Haro A., and Guzman M. (2000) The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase Mol. Pharmacol. 58, 814–820.PubMedGoogle Scholar
  102. Sagan S., Venance L., Torrens Y., Cordier J., Glowinski J., and Giaume C. (1999) Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur. J. Neurosci. 11, 691–699.PubMedCrossRefGoogle Scholar
  103. Sanchez C., de Ceballos M. L., del Pulgar T. G., et al. (2001) Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor Cancer Res. 61, 5784–5789.PubMedGoogle Scholar
  104. Sanchez C., Galve-Roperh I., Rueda D., and Guzman M. (1998) Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes Mol. Pharmacol. 54, 834–843.PubMedGoogle Scholar
  105. Schlicker E. and Kathmann M. (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22, 565–572.PubMedCrossRefGoogle Scholar
  106. Shen M. and Thayer S. A. (1998a) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54, 459–462.PubMedGoogle Scholar
  107. Shen M. and Thayer S. A. (1998b) The cannabinoid agonist Win55, 212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res. 783, 77–84.PubMedCrossRefGoogle Scholar
  108. Sinor A. D., Irvin S. M., and Greenberg D. A. (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. 278, 157–160.PubMedCrossRefGoogle Scholar
  109. Skaper S. D., Buriani A., Dal Toso R., et al. (1996) The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA 93, 3984–3989.PubMedCrossRefGoogle Scholar
  110. Slipetz D. M., O’Neill G. P., Favreau L., et al. (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase Mol. Pharmacol. 48, 352–361.PubMedGoogle Scholar
  111. Smart D. and Jerman J. C. (2000) Anandamide: an endogenous activator of the vanilloid receptor. Trends Pharmacol. Sci. 21, 134.PubMedCrossRefGoogle Scholar
  112. Sugiura T., Kodaka T., Kondo S., et al. (1997b) Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells J. Biochem. (Tokyo) 122, 890–895.Google Scholar
  113. Sugiura T., Kodaka T., Kondo S., et al. (1996) 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma × glioma hybrid NG108-15 cells Biochem. Biophys. Res. Commun. 229, 58–64.PubMedCrossRefGoogle Scholar
  114. Sugiura T., Kodaka T., Kondo S., et al. (1997a) Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma × glioma hybrid NG108-15 cells Biochem. Biophys. Res. Commun. 233, 207–210.PubMedCrossRefGoogle Scholar
  115. Sugiura T., Kodaka T., Nakane S., et al. (1999) Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds J. Biol. Chem. 274, 2794–2801.PubMedCrossRefGoogle Scholar
  116. Sugiura T., Yoshinaga N., Kondo S., Waku K., and Ishima Y. (2000) Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain. Biochem. Biophys. Res. Commun. 271, 654–658.PubMedCrossRefGoogle Scholar
  117. Tsou K., Brown S., Sanudo-Pena M. C., Mackie K., and Walker J. M. (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393–411.PubMedCrossRefGoogle Scholar
  118. van der Stelt M., Veldhuis W. B., Bar P. R., Veldink G. A., Vliegenthart J. F., and Nicolay K. (2001a) Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 21, 6475–6479.PubMedGoogle Scholar
  119. van der Stelt M., Veldhuis W. B., Maccarrone M., et al. (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol. Neurobiol. 26, 317–346.PubMedCrossRefGoogle Scholar
  120. van der Stelt M., Veldhuis W. B., van Haaften G. W., et al. (2001b) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21, 8765–8771.PubMedGoogle Scholar
  121. Veldhuis W., Van der Stelt M., Wadman M., et al. (2003) Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. in press.Google Scholar
  122. Vogel Z., Barg J., Levy R., Saya D., Heldman E., and Mechoulam R. (1993) Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase J. Neurochem. 61, 352–355.PubMedCrossRefGoogle Scholar
  123. Walter L. and Stella N. (2004) Cannabinoids and neuroinflammation Br. J. Pharmacol. 141, 775–785.PubMedCrossRefGoogle Scholar
  124. Wartmann M., Campbell D., Subramanian A., Burstein S. H., and Davis R. J. (1995) The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide FEBS Lett 359, 133–136.PubMedCrossRefGoogle Scholar
  125. Wilson R. I. and Nicoll R. A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588–592.PubMedCrossRefGoogle Scholar
  126. Zygmunt P. M., Petersson J., Andersson D. A., et al. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452–457.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2005

Authors and Affiliations

  1. 1.Endocannabinoid Research GroupInstitute of Biomolecular Chemistry, Consiglio Nazionale delle RicerchePozzuoli (NA)Italy

Personalised recommendations